NASDAQ:DFFN - Diffusion Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.29 0.00 (0.00 %) (As of 11/21/2018 04:28 AM ET)Previous Close$0.2901Today's Range$0.28 - $0.3252-Week Range$0.28 - $2.08Volume273,300 shsAverage Volume426,223 shsMarket Capitalization$15.96 millionP/E Ratio-0.25Dividend YieldN/ABeta-1.43 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Diffusion Pharmaceuticals Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer. Its lead product candidate is transcrocetinate sodium, which has initiated Phase 3 trials for the treatment of glioblastoma multiforme (GBM); Phase 2 clinical trials for the treatment of pancreatic cancer; Phase 2/3 clinical trials for the treatment of metastatic brain cancer; and Phase 2 trial for the treatment of stroke. The company is also developing RES-529, a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of age-related macular degeneration; and is in pre-clinical development stage for the treatment of oncology primarily GBM. Diffusion Pharmaceuticals Inc. was founded in 2001 and is headquartered in Charlottesville, Virginia. Receive DFFN News and Ratings via Email Sign-up to receive the latest news and ratings for DFFN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DFFN Previous Symbol CUSIPN/A Webwww.diffusionpharma.com Phone434-220-0718 Debt Debt-to-Equity RatioN/A Current Ratio12.30 Quick Ratio12.30 Price-To-Earnings Trailing P/E Ratio-0.25 Forward P/E Ratio-0.67 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$0.1620 per share Price / Cash1.79 Book Value$0.42 per share Price / Book0.69 Profitability EPS (Most Recent Fiscal Year)($1.14) Net Income$-1,360,000.00 Net MarginsN/A Return on Equity-27.49% Return on Assets-24.11% Miscellaneous Employees11 Outstanding Shares50,640,000Market Cap$15.96 million OptionableNot Optionable Diffusion Pharmaceuticals (NASDAQ:DFFN) Frequently Asked Questions What is Diffusion Pharmaceuticals' stock symbol? Diffusion Pharmaceuticals trades on the NASDAQ under the ticker symbol "DFFN." How were Diffusion Pharmaceuticals' earnings last quarter? Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) posted its quarterly earnings results on Wednesday, November, 14th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.06) by $0.07. View Diffusion Pharmaceuticals' Earnings History. When is Diffusion Pharmaceuticals' next earnings date? Diffusion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, April 2nd 2019. View Earnings Estimates for Diffusion Pharmaceuticals. What price target have analysts set for DFFN? 1 brokers have issued twelve-month price targets for Diffusion Pharmaceuticals' shares. Their forecasts range from $1.00 to $1.00. On average, they anticipate Diffusion Pharmaceuticals' stock price to reach $1.00 in the next year. This suggests a possible upside of 244.8% from the stock's current price. View Analyst Price Targets for Diffusion Pharmaceuticals. What is the consensus analysts' recommendation for Diffusion Pharmaceuticals? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Diffusion Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Diffusion Pharmaceuticals. Has Diffusion Pharmaceuticals been receiving favorable news coverage? Media headlines about DFFN stock have trended somewhat positive this week, InfoTrie Sentiment reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Diffusion Pharmaceuticals earned a news sentiment score of 0.9 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 8.0 out of 10, indicating that recent media coverage is very likely to have an effect on the stock's share price in the immediate future. Who are some of Diffusion Pharmaceuticals' key competitors? Some companies that are related to Diffusion Pharmaceuticals include Novan (NOVN), Humanigen (HGEN), Merrimack Pharmaceuticals (MACK), Forward Pharma A/S (FWP), Sophiris Bio (SPHS), GT Biopharma (GTBP), Avenue Therapeutics (ATXI), Neos Therapeutics (NEOS), Acasti Pharma (ACST), Leap Therapeutics (LPTX), Vistagen Therapeutics (VTGN), Bellerophon Therapeutics (BLPH), Helix Biopharma (HBPCF), Nemus Bioscience (NMUS) and Trevena (TRVN). Who are Diffusion Pharmaceuticals' key executives? Diffusion Pharmaceuticals' management team includes the folowing people: Mr. David G. Kalergis, Co-Founder, CEO & Chairman (Age 69)Dr. John L. Gainer, Co-Founder, Chief Scientific Officer & Director (Age 79)Mr. William Karl Hornung, Chief Financial Officer (Age 49)Mr. Thomas E. Byrne, Gen. Counsel (Age 61)Dr. David Randolph Jones M.D., Chief Medical Officer (Age 55) How do I buy shares of Diffusion Pharmaceuticals? Shares of DFFN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Diffusion Pharmaceuticals' stock price today? One share of DFFN stock can currently be purchased for approximately $0.29. How big of a company is Diffusion Pharmaceuticals? Diffusion Pharmaceuticals has a market capitalization of $15.96 million. The company earns $-1,360,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis. Diffusion Pharmaceuticals employs 11 workers across the globe. What is Diffusion Pharmaceuticals' official website? The official website for Diffusion Pharmaceuticals is http://www.diffusionpharma.com. How can I contact Diffusion Pharmaceuticals? Diffusion Pharmaceuticals' mailing address is 1317 CARLTON AVENUE SUITE 200, CHARLOTTESVILLE VA, 22902. The company can be reached via phone at 434-220-0718 or via email at [email protected] MarketBeat Community Rating for Diffusion Pharmaceuticals (NASDAQ DFFN)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 104 (Vote Outperform)Underperform Votes: 90 (Vote Underperform)Total Votes: 194MarketBeat's community ratings are surveys of what our community members think about Diffusion Pharmaceuticals and other stocks. Vote "Outperform" if you believe DFFN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DFFN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/21/2018 by MarketBeat.com StaffFeatured Article: What are the benefits of a balanced fund?